Catalog No.: PC-24111Not For Human Use, Lab Use Only.
Amezalpat (TPST-1120, TPST1120) is potent, selective and orally bioavailable inhibitor of peroxisome proliferator-activated receptor α (PPARα) with IC50 of 0.04 uM (human PPARα), >250-fold selectivity over the other PPAR isoforms (PPAR β/δ and γ).
Amezalpat (TPST-1120, TPST1120) is potent, selective and orally bioavailable inhibitor of peroxisome proliferator-activated receptor α (PPARα) with IC50 of 0.04 uM (human PPARα), >250-fold selectivity over the other PPAR isoforms (PPAR β/δ and γ).
TPST-1120 exhibits potent anti-tumor immune responses and significant tumor regression in syngeneic models of breast, lung, colon, pancreatic and melanoma in addition to xenograft models of CLL, AML, pancreatic and melanoma cancers as a monotherapy or in combination with chemotherapy.
Combination of TPST-1120 plus anti-PD-1 therapy resulted in synergistic tumor reduction and durable antitumor immunity in multiple syngeneic mouse models.
